KFAS
DGX icon

Keating Financial Advisory Services’s Quest Diagnostics DGX Stock Holding History

Keating Financial Advisory Services’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$164K Sell
772
-155
-17% -$30.4K 0.02% 387
2026
Q1 		$182K Sell
927
-141
-13% -$27.4K 0.03% 346
2025
Q4 		$185K Buy
+1,068
New +$194K 0.03% 381

Other funds holding DGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Keating Financial Advisory Services's DGX Position: Q2 2026 in Review

Keating Financial Advisory Services reduced its Quest Diagnostics (DGX) stake by 17% in Q2 2026, selling an estimated $30.4K and leaving 772 shares worth $164K. The position accounts for 0.02% of the portfolio, ranked #387.

Keating Financial Advisory Services first reported a position in DGX in Q4 2025 and has held it in 3 quarters since. The position peaked at $185K in Q4 2025. 1,111 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Keating Financial Advisory Services held 772 shares of Quest Diagnostics worth $164K as of Q2 2026.
  • Keating Financial Advisory Services sold 155 Quest Diagnostics shares in Q2 2026, an estimated $30.4K.
  • Quest Diagnostics made up 0.02% of Keating Financial Advisory Services's portfolio in Q2 2026, its #387 holding.
  • Keating Financial Advisory Services first reported a position in Quest Diagnostics in Q4 2025 and has held it in 3 quarters since.
  • Keating Financial Advisory Services's Quest Diagnostics position peaked at $185K in Q4 2025.
  • 1,111 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.